Abrocitinib ne na baka, ƙananan kwayoyin halitta, Janus kinase (JAK) 1 mai hanawa a cikin ci gaba don kula da manya da matasa tare da matsakaici zuwa matsakaicin atopic dermatitis.

Abrocitinib yana ƙarƙashin bincike a gwaji na asibiti NCT03796676 (JAK1 Inhibitor Tare da Magungunan Magungunan Magunguna a cikin Matasa Tare da Atopic Dermatitis).

A halin yanzu Pfizer yana haɓaka Abrocitinib don maganin cututtukan fata (eczema). Mai hanawa Janus kinase 1 (JAK1) ne na baki sau ɗaya kowace rana.

Atopic dermatitis (AD) cuta ce mai rikitarwa, na yau da kullun, mai kumburin fata wanda ke da alaƙa da pruritic, matsanancin ƙaiƙayi, da raunukan eczematous wanda ke shafar kusan 25% na yara da 2% zuwa 3% na manya a duniya. Abrocitinib shine mai hanawa na Janus kinase-1 (JAK1) enzyme wanda ke hana tsarin kumburi. Saboda haka, mun yi niyya don tantance inganci da amincin abrocitinib don matsakaici-zuwa mai tsanani AD.

Abrocitinib a cikin kashi 100 MG ko 200 MG yana da tasiri, jurewa, kuma magani mai ban sha'awa a cikin zalunta marasa lafiya tare da matsakaici-zuwa mai tsanani atopic dermatitis. Duk da haka, binciken ya fi dacewa da tasiri na abrocitinib 200 MG akan 100 MG, amma sakamako masu illa irin su tashin zuciya da ciwon kai suna iya faruwa fiye da 200 MG.